Redwood Investment Management LLC Invests $2.20 Million in Halozyme Therapeutics, Inc. $HALO

Redwood Investment Management LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 28,149 shares of the biopharmaceutical company’s stock, valued at approximately $2,203,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Empowered Funds LLC bought a new stake in Halozyme Therapeutics in the first quarter valued at approximately $755,000. Acadian Asset Management LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $195,000. Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. raised its stake in Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 64,103 shares of company stock worth $5,226,496. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Trading Down 2.1%

HALO stock opened at $107.06 on Thursday. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $109.66. The company has a market capitalization of $12.15 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85. The company’s 50-day simple moving average is $85.50 and its 200 day simple moving average is $74.39. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of research analyst reports. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Citizens Jmp lifted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.